Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Stage III research for nodular acne Cipher Pharmaceuticals Inc. today announced that it has completed patient enrolment in its Stage III safety study of CIP-ISOTRETINOIN, the Company’s novel, patented formulation of isotretinoin, which can be used in the treatment of severe, nodular acne.S http://sildenafilae.com/silagra-wiki-info-read-before-using.html . Food and Drug Administration .
Gross R&D expenditures for the 4th quarter were $3.0 million, and reported R&D expenses were $0.3 million. OG&A expenses for Q4 2009 had been $1.1 million, compared with $0.9 million in the same period last year. Loss for the 90 days ended December 31, 2009 was $0.6 million , weighed against a lack of $0.5 million in the same period this past year. The Company’s budget remained solid at year-end. As at December 31, 2009, Cipher had cash of $9.0 million, compared with $9.at December 31 9 million as, 2008. Product Update ————- – During 2009, Lipofen monthly prescriptions showed continuous growth, and Cipher can be hopeful that this pattern will continue as Kowa raises penetration of the primary care physicians in its targeted regions and expands its sales force.